TNFAIP3 gene polymorphisms are associated with response to TNF blockade in psoriasis

Journal of Investigative Dermatology

Volumn 132, Issue 3 PART 1, 2012, Pages 593-600

  Tejasvi, Trilokraj ^a   Stuart, Philip E ^a   Chandran, Vinod ^b   Voorhees, John J ^a   Gladman, Dafna D ^b   Rahman, Proton ^c   Elder, James T ^a,d   Nair, Rajan P ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b TORONTO WESTERN HOSPITAL   (Canada)

^c MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^d VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB;

ADULT; ALLELE; ARTICLE; EXON; FEMALE; FOLLOW UP; GENE; GENETIC ASSOCIATION; HAPLOTYPE; HUMAN; INTRON; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; SELF EVALUATION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; TUMOR NECROSIS FACTOR ALPHA INDUCED PROTEIN 3 GENE; VISUAL ANALOG SCALE;

EID: 84857037386     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2011.376     Document Type: Article

References (48)

1. Arends S, Brouwer E, van der Veer E et al. (2011) Baseline predictors of response and discontinuation of TNF-alpha blocking therapy in ankylosing spondylitis: A prospective longitudinal observational cohort study. Arthritis Res Ther 13:R94
2. Chen H, Poon A, Yeung C et al. (2011) A genetic risk score combining ten psoriasis risk loci improves disease prediction. PLoS One 6:e19454
3. Cordoro KM, Feldman SR (2007) TNF-alpha inhibitors in dermatology. Skin Therapy Lett 12:4-6
4. Cormier C, Bosse Y, Mfuna L et al. (2009) Polymorphisms in the tumour necrosis factor alpha-induced protein 3 (TNFAIP3) gene are associated with chronic rhinosinusitis. J Otolaryngol Head Neck Surg 38:133-41
5. Eder L, Chandran V, Schentag CT et al. (2010) Time and predictors of response to tumour necrosis factor-alpha blockers in psoriatic arthritis: An analysis of a longitudinal observational cohort. Rheumatology (Oxford) 49:1361-6
6. Elder JT, Bruce AT, Gudjonsson JE et al. (2010) Molecular dissection of psoriasis: Integrating genetics and biology. J Invest Dermatol 130: 1213-26
7. Ellinghaus E, Ellinghaus D, Stuart PE et al. (2010) Genome-wide association study identifies a psoriasis susceptibility locus at TRAF3IP2. Nat Genet 42:991-5
8. Faul F, Erdfelder E, Lang AG et al. (2007) G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 39:175-91
9. Fung EY, Smyth DJ, Howson JM et al. (2009) Analysis of 17 autoimmune disease-associated variants in type 1 diabetes identifies 6q23/TNFAIP3 as a susceptibility locus. Genes Immun 10:188-91
10. Gateva V, Sandling JK, Hom G et al. (2009) A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus. Nat Genet 41:1228-33
11. Goring HH, Terwilliger JD, Blangero J (2001) Large upward bias in estimation of locus-specific effects from genomewide scans. Am J Hum Genet 69:1357-69 (Pubitemid 33124216)
12. Gottlieb AB, Matheson RT, Lowe N et al. (2003) A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 139:1627-32; discussion 1632 (Pubitemid 37523083)
13. Graham RR, Cotsapas C, Davies L et al. (2008) Genetic variants near TNFAIP3 on 6q23 are associated with systemic lupus erythematosus. Nat Genet 40:1059-61
14. Gudjonsson JE, Karason A, Antonsdottir AA et al. (2002) HLA-Cw6-positive and HLA-Cw6-negative patients with Psoriasis vulgaris have distinct clinical features. J Invest Dermatol 118:362-5 (Pubitemid 34158494)
15. Han JW, Zheng HF, Cui Y et al. (2009) Genome-wide association study in a Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus. Nat Genet 41:1234-7
16. Heyninck K, De Valck D, Vanden Berghe W et al. (1999) The zinc finger protein A20 inhibits TNF-induced NF-kappaB-dependent gene expression by interfering with an RIP-or TRAF2-mediated transactivation signal and directly binds to a novel NF-kappaB-inhibiting protein ABIN. J Cell Biol 145:1471-82 (Pubitemid 29310004)
17. Huffmeier U, Uebe S, Ekici AB et al. (2010) Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis. Nat Genet 42:996-9
18. Koczan D, Drynda S, Hecker M et al. (2008) Molecular discrimination of responders and nonresponders to anti-TNF alpha therapy in rheumatoid arthritis by etanercept. Arthritis Res Ther 10:R50
19. Kooloos WM, de Jong DJ, Huizinga TW et al. (2007) Potential role of pharmacogenetics in anti-TNF treatment of rheumatoid arthritis and Crohn's disease. Drug Discov Today 12:125-31 (Pubitemid 46176662)
20. Leonardi CL, Powers JL, Matheson RT et al. (2003) Etanercept as monotherapy in patients with psoriasis. N Engl J Med 349:2014-22 (Pubitemid 37448924)
21. Li L, Soetandyo N, Wang Q et al. (2009) The zinc finger protein A20 targets TRAF2 to the lysosomes for degradation. Biochim Biophys Acta 1793:346-53
22. Liu C, Batliwalla F, Li W et al. (2008) Genome-wide association scan identifies candidate polymorphisms associated with differential response to anti-TNF treatment in rheumatoid arthritis. Mol Med 14:575-81
23. Liu YC, Penninger J, Karin M (2005) Immunity by ubiquitylation: A reversible process of modification. Nat Rev Immunol 5:941-52 (Pubitemid 41746763)
24. Mauro C, Pacifico F, Lavorgna A et al. (2006) ABIN-1 binds to NEMO/ IKKgamma and co-operates with A20 in inhibiting NF-kappaB. J Biol Chem 281:18482-8 (Pubitemid 44035507)
25. Maxwell JR, Potter C, Hyrich KL et al. (2008) Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis. Hum Mol Genet 17:3532-8
26. Musone SL, Taylor KE, Lu TT et al. (2008) Multiple polymorphisms in the TNFAIP3 region are independently associated with systemic lupus erythematosus. Nat Genet 40:1062-4
27. Nair RP, Duffin KC, Helms C et al. (2009) Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet 41:199-204
28. Nair RP, Guo SW, Jenisch S et al. (1995) Scanning chromosome 17 for psoriasis susceptibility: Lack of evidence for a distal 17q locus. Hum Hered 45:219-30
29. O'Rielly DD, Roslin NM, Beyene J et al. (2009) TNF-alpha-308 G/A polymorphism and responsiveness to TNF-alpha blockade therapy in moderate to severe rheumatoid arthritis: A systematic review and metaanalysis. Pharmacogenomics J 9:161-7
30. Opipari AW Jr, Boguski MS, Dixit VM (1990) The A20 cDNA induced by tumor necrosis factor alpha encodes a novel type of zinc finger protein. J Biol Chem 265:14705-8
31. Papp KA, Tyring S, Lahfa M et al. (2005) A global phase III randomized controlled trial of etanercept in psoriasis: Safety, efficacy, and effect of dose reduction. Br J Dermatol 152:1304-12 (Pubitemid 40933433)
32. Pearce DJ, Nelson AA, Fleischer AB et al. (2006) The cost-effectiveness and cost of treatment failures associated with systemic psoriasis therapies. J Dermatolog Treat 17:29-37 (Pubitemid 43247305)
33. Pierik M, Rutgeerts P, Vlietinck R et al. (2006) Pharmacogenetics in inflammatory bowel disease. World J Gastroenterol 12:3657-67 (Pubitemid 43950942)
34. Plant D, Bowes J, Potter C et al. (2011) Genome-wide association study of genetic predictors of anti-tumor necrosis factor treatment efficacy in rheumatoid arthritis identifies associations with polymorphisms at seven loci. Arthritis Rheum 63:645-53
35. Plenge RM, Cotsapas C, Davies L et al. (2007) Two independent alleles at 6q23 associated with risk of rheumatoid arthritis. Nat Genet 39:1477-82 (Pubitemid 350191346)
36. Purcell S, Neale B, Todd-Brown K et al. (2007) PLINK: A tool set for wholegenome association and population-based linkage analyses. Am J Hum Genet 81:559-75 (Pubitemid 47330214)
37. Seitz M, Wirthmuller U, Moller B et al. (2007) The 308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients. Rheumatology (Oxford) 46:93-6 (Pubitemid 44932793)
38. Sobell JM, Kalb RE, Weinberg JM (2009) Management of moderate to severe plaque psoriasis (part I): Clinical update on antitumor necrosis factor agents. J Drugs Dermatol 8:147-54
39. Strange A, Capon F, Spencer CC et al. (2010) A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat Genet 42:985-90
40. Stuart PE, Nair RP, Ellinghaus E et al. (2010) Genome-wide association analysis identifies three psoriasis susceptibility loci. Nat Genet 42:1000-4
41. Sun LD, Cheng H, Wang ZX et al. (2010) Association analyses identify six new psoriasis susceptibility loci in the Chinese population. Nat Genet 42:1005-9
42. Tejasvi T, Stuart PE, Nair RP et al. (2008) Initial pharmacogenomic assessment of TNF-alpha and TRAF1 polymorphisms in psoriasis: Response to TNF blockers and other systemic therapies. J Invest Dermatol 128:S74
43. Thomson W, Barton A, Ke X et al. (2007) Rheumatoid arthritis association at 6q23. Nat Genet 39:1431-3 (Pubitemid 350191348)
44. Trynka G, Zhernakova A, Romanos J et al. (2009) Coeliac disease-associated risk variants in TNFAIP3 and REL implicate altered NF-kappaB signalling. Gut 58:1078-83
45. Vereecke L, Beyaert R, van Loo G (2009) The ubiquitin-editing enzyme A20 (TNFAIP3) is a central regulator of immunopathology. Trends Immunol 30:383-91
46. Werner SL, Kearns JD, Zadorozhnaya V et al. (2008) Encoding NF-kappaB temporal control in response to TNF: Distinct roles for the negative regulators IkappaBalpha and A20. Genes Dev 22:2093-101
47. Wertz IE, O'Rourke KM, Zhou H et al. (2004) De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. Nature 430:694-9 (Pubitemid 39061687)
48. Zetoune FS, Murthy AR, Shao Z et al. (2001) A20 inhibits NF-kappa B activation downstream of multiple Map3 kinases and interacts with the I kappa B signalosome. Cytokine 15:282-98 (Pubitemid 34587630)